SONIA L ALI M.D. NPI 1730451089

NPI Information

  • NPI: 1730451089
  • Provider Name: SONIA L ALI, M.D.
  • Classification: Internal Medicine - 207RH0003X
  • Specialization: Hematology & Oncology
  • Entity Type: Individual
  • PECOS Registration: Yes
  • Address: 10710 N TORREY PINES RD
    LA JOLLA, CA
    ZIP 92037
  • Phone: (858) 554-8788

Map and Directions

Get Directions

NPI Details

Sonia L Ali, M.D. is a hematology and oncology internal medicine in La Jolla, CA with 16 years of experience. The provider is an internist doctor of osteopathy that specializes in the treatment of the combination of hematology and oncology disorders. A doctor of osteopathy that is board eligible/certified by the American Osteopathic Board of Internal Medicine WAS able to obtain a Certificate of Special Qualifications in the field of Hematology and Oncology. The Certificate is NO longer offered. Sonia L Ali, M.D. NPI is 1730451089. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a female.

The provider's business location address is:

10710 N TORREY PINES RD
LA JOLLA, CA
ZIP 92037-035
Phone: (858) 554-8788
Fax: (858) 554-8946

The NPI 1730451089 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

  • Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram (HCPCS:Q5101)
  • Injection, azacitidine, 1 mg (HCPCS:J9025)
  • Injection, paclitaxel, 1 mg (HCPCS:J9267)
  • Injection, pembrolizumab, 1 mg (HCPCS:J9271)
  • Injection, denosumab, 1 mg (HCPCS:J0897)
  • Injection, aprepitant, 1 mg (HCPCS:J0185)
  • Injection, trastuzumab-anns, biosimilar, (kanjinti), 10 mg (HCPCS:Q5117)
  • Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
  • Injection, fulvestrant, 25 mg (HCPCS:J9395)
  • Injection, granisetron hydrochloride, 100 mcg (HCPCS:J1626)
  • Injection, granisetron, extended-release, 0.1 mg (HCPCS:J1627)
  • Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
  • Injection of additional new drug or substance into vein (HCPCS:96375)
  • Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
  • Injection, zoledronic acid, 1 mg (HCPCS:J3489)
  • Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
  • Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg (HCPCS:J9201)
  • Injection, pegfilgrastim, excludes biosimilar, 0.5 mg (HCPCS:J2506)
  • Injection of drug or substance under skin or into muscle (HCPCS:96372)
  • Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
  • Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
  • Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
  • Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
  • Unclassified drugs (HCPCS:J3490)
  • Irrigation of implanted venous access drug delivery device (HCPCS:96523)
  • Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
  • Collection of blood sample from implanted device (HCPCS:36591)
  • Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
  • Infusion, normal saline solution, 250 cc (HCPCS:J7050)
  • New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
  • Transfusion of blood or blood products (HCPCS:36430)
  • Infusion into a vein for hydration, each additional hour (HCPCS:96361)
  • Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
  • Application of on-body injector for under skin injection (HCPCS:96377)
  • New patient office or other outpatient visit, 45-59 minutes (HCPCS:99204)
  • Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
  • Follow-up hospital inpatient care per day, typically 35 minutes (HCPCS:99233)
  • Insertion of needle into vein for collection of blood sample (HCPCS:36415)
  • Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
  • Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)

The enumeration date for this NPI number is 2/2/2012 and was last updated on 3/16/2021.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available:

No. Taxonomy Code Taxonomy Clasification Taxonomy Specialization License Number License State Primary
1207RH0000XInternal MedicineHematologyA123537CALIFORNIANo
2207RH0003XInternal MedicineHematology & OncologyA123537CALIFORNIAYes
3207RX0202XInternal MedicineMedical OncologyA123537CALIFORNIANo

What is NPI?

NPI stands for National Provider Identifier. The NPI is a 10-digit identification number that is completely unique. The NPI number by itself does not contain any identifiable information such as a provider’s speciality or location. The NPI is assigned to individuals or organizacions for their lifespan and it is independent of key provider information type updates like a change of practices, location or speciality.

This page was last updated on: 11/21/2025

NPI Synchronization or Removal

All materials and services on this site are provided on an "as is" and "as available" basis without warranty of any kind. The NPI record is maintained by the National Plan & Provider Enumeration System (NPPES) and anyone may request this information and other NPPES health care provider data from HHS under The Freedom of Information Act (FOIA), Title 5 of the United States Code, section 552. To update the NPI records please contact the NPPES.